Imagine your favorite pharma stock suddenly jumping more than 12% in a single day. That’s exactly what happened with Natco Pharma share price on February 16, 2026! Investors are buzzing as the stock shot up to a high of ₹932, leaving many wondering what’s behind this exciting rally.
The Natco Pharma share price climbed from a previous close of ₹823.85 to around ₹921.45 by mid-morning (11:25 AM IST). That’s a solid +11.85% gain, with heavy trading — almost 10 million shares changed hands on the NSE alone. After weeks of sideways movement, this breakout feels like a fresh start for shareholders.
Main Reasons for the Jump
The biggest spark? Natco got the green light from CDSCO to make and sell generic Semaglutide injections in India. You know Semaglutide — it’s the powerhouse ingredient in popular drugs like Ozempic and Wegovy for diabetes and weight loss. Demand for these GLP-1 medicines is huge worldwide, and now Natco can offer an affordable version here. Launch is planned for March 2026, which could bring in big sales volumes fast.
Adding to the cheer, Natco also grabbed tentative USFDA approval for generic Erdafitinib (copy of Balversa), a cancer drug for advanced bladder issues. As a first-to-file player, this gives Natco strong entry into a $60 million US market, boosting its high-profit oncology lineup.
Don’t forget the small but sweet interim dividend of ₹1.50 per share. The ex-date is February 18, 2026 — so folks are buying now to grab that payout.
Natco Pharma Q3 FY26 Numbers
Natco’s latest quarter shows steady growth despite some ups and downs.
- Total Revenue: ₹705.4 Cr (up 8.3% from last year)
- Net Profit: ₹151.3 Cr (up 14.3%)
- EBITDA Margin: 30.7%
- EPS: ₹8.46 (up 13.9%)
Margins dipped a bit, but overall, profits grew nicely year-on-year.
What’s Next for Natco Pharma Share Price?
CEO Rajeev Nannapaneni talked about focusing on tough generics and smart buys. The company has around ₹2,500 crore in cash ready for deals, like growing the Adcock Ingram business. Crop health sciences also did well this quarter, spreading out income beyond just medicines.
Management eyes ₹4,300 crore revenue by end of FY26, thanks to fresh launches.
On charts, the Natco Pharma share price smashed past ₹900 with strong volume. Next hurdles? ₹980 and ₹1,050. Analysts mostly say “Buy” or “Hold,” with average targets around ₹925–₹980. Some dream big at ₹1,200+ if Semaglutide takes off quickly.
A few caution flags exist — like margin squeeze and some “Sell” calls on technical sites. Keep an eye on how new products perform.
If you’re watching pharma stocks, today’s action makes Natco Pharma share price one to track closely. Could this be the start of a bigger run?
Disclaimer: This content is for informational purposes only and should not be considered professional [financial/legal/medical] advice. Always seek the advice of a qualified professional before making any decisions based on this information.
Sources & References
Business Standard, NDTV Profit, The Hindu, ScanX News
Yogesh Kolhe is a business and market news writer covering the share market, company earnings, and gold and silver price movements, with a strong focus on the automobile sector. A Mechanical Engineering graduate with 5 years of share market experience, he provides data-driven, reliable insights into market and industry trends.
